Nippon Kayaku Kabushiki Kaisha

Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

Other

Takara Shuzo Co., Inc.

Orion-yhtyma Oy

Takara Shuzo Kabushiki Kaisha

Takaru Shuzo Co., Ltd.

Tetsushi Saino

Hamao Umezawa

Takaaki Aoyagi

Tomio Takeuchi

Michinori Koyama

Lauri V Kangas

Hisao Ekimoto

Rinzo Nishizawa

Osamu Miyazaki

Anni Warri

Christer Granberg

Yoshihisa Umeda

Junpei Itoh

Tadashi Shirai

Ikunoshin Kato

Masao Suzuki

Masaaki Ishizuka

Teruya Nakamura

Tomohisa Takita

Takashi Terada

Tetsuya Someno

Tsugio Tomiyoshi

Kyuichi Nemoto

Makoto Moriguchi

Shinichi Ishii

Terukatsu Sakurai

Katsushige Ikai

Katsutoshi Takahashi

Yasuhiko Muraoka

Yasuhisa Tashiro

Hamao Umezawa, Deceased

Toru Kurome

Yoshinobu Miyazawa

Takaaki Ohkuma

Kazuo Kato

Hironobu Hiraga

Akihiro Mashiba

Takako Mae

Chihiro Nishimura

Takumi Yamashita

Masao Yoshida

Kazuteru Hagita

Junpei It&ouml;h

Keiko Miyazaki

A medicament for prophylaxis or treatment of bone marrow suppression, for treatment of infectious diseases and for increasing the number of leukocytes, which comprise as an active ingredient a sulphostin-related compound represented by general formula (I): wherein n is an integer of 0 to 3, or a pharmacologically acceptable salt thereof.

Medicament for treatment of bone marrow suppression, for treatment of infectious diseases and for increasing the number of leukocytes

Disclosed is use of nonsteroidal anti-estrogen compounds such as toremifene citrate as active ingredient for treating autoimmune diseases.

Remedy for autoimmune diseases

The invention provides crystalline deoxyspergualin trihydrochloride, a process for the preparation of the same and a suppository composition containing the same. The compound and composition has antitumor and immunosuppressive activity.

Crystalline deoxyspergualin, process for its preparation and suppository

Novel spergualin-related compounds represented by the general formula (I): ##STR1## wherein X represents --(CH.sub.2).sub.1-5 -- or a phenylene group which may be substituted; m represents 0, 1 or 2; n represents 1 or 2; and R.sub.1 represents --(CH.sub.2).sub.1-3 --COOH, and pharmacologically acceptable salts thereof, possess an immunopotentiating activity, and are expected to be useful as immunopotentiators applicable to warm blooded animals.

Spergualin-related compound and use thereof

The present invention relates to novel spergualin-related compounds represented by the general formula [I]: ##STR1## wherein X is --(CH.sub.2).sub.1.about.5 or ##STR2## Y is a hydrogen atom or a residue obtained by removing a hydroxyl group from the carboxyl group of an amino acid or a peptide; m is 0, 1 or 2 and n is 1 or 2, with the proviso that Y is not a hydrogen atom when n is 2 and m is 0. This compounds are stable and exhibit a high immunosuppressive activity.

Novel spergualin-related compounds and compositions

An agent for relieving radiogenic or drug-induced side effects, characterized by comprising a spergualin derivative of the following formula (I):

Method for relieving radiogenic or drug-induced side effects

Process for purifying spergualin-related compounds and their synthetic intermediates, by subjecting a solution containing such spergualin-related compounds or intermediates to electrodialysis and/or reverse osmosis.

Process for the purification of spergualin-related compounds

The present invention relates to novel Spergualin-related compounds represented by the general formula [I] ##STR1## (wherein X is ##STR2## R is --H or --CH.sub.2 OH; R.sub.1 is --H, ##STR3## R.sub.2 is a residue obtained by removing, from an amino acid or peptide, the hydroxyl group of the carboxyl group and, when R.sub.1 is a group other than --H, R.sub.2 is same as R.sub.1), or a pharmacologically acceptable salt thereof. Said compounds or salts thereof have an immuno-modulating action.

Novel spergualin-related compounds and process for producing the same

A stable, non-hygroscopic, crystalline .gamma.-form of bestatin is prepared from the .alpha.- or .beta.-form of bestatin by heating at a temperature of from about 148.degree. C. to the melting point of bestatin, or by suspending or kneading in certan specified solvents.

Crystalline upsilon-form bestatin and processes for its preparation

A stable, non-hygroscopic, crystalline .gamma.-form of bestatin is prepared from the .alpha.- or .beta.-form of bestatin by heating at a temperature of from about 148.degree. C. to the melting point of bestatin, or by suspending or kneading in certain specified solvents.

Crystalline gamma-form bestatin and processes for its preparation

The present invention relates to new easily filtrable, non-hygroscopic N-benzyloxycarbonyl-L-threonine amide hemihydrate.

N-benzyloxycarbonyl-L-threonine amide hemihydrate

Growing community of inventors

Yono, Japan

Tetsushi Saino